Cosentino Marco, Legnaro Massimiliano, Luini Alessandra, Ferrari Marco, Sodergren Mikael, Pacchetti Barbara, Marino Franca
Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy.
Curaleaf International, London, United Kingdom.
Cannabis Cannabinoid Res. 2023 Dec;8(6):999-1007. doi: 10.1089/can.2022.0008. Epub 2022 Aug 5.
In this study, the effects of the cannabinoid CBD were assessed on cyclooxygenase (COX)-1 and COX-2 expression and activity in resting and activated human neutrophils (polymorphonuclear [PMN] leukocytes). COX expression was measured at the mRNA levels, whereas COX activity was assessed by enzyme-linked immunosorbent assay measurement of prostaglandin (PG)E. experiments in a standard commercial acellular assay of COX-1/COX-2 activity completed the study. Results show that CBD profoundly inhibits expression of COX-1 and COX-2 mRNA in activated PMN, however, without any significant consequences for PGE production. CBD, however, was able to induce a slight but significant direct inhibition of COX-2 in the acellular model. The effects of CBD occur in the μM concentration range, which is attained in humans with therapeutic doses of the drug, suggesting the clinical relevance of these findings.
在本研究中，评估了大麻素CBD对静息和活化的人中性粒细胞（多形核[PMN]白细胞）中环氧化酶（COX）-1和COX-2表达及活性的影响。在mRNA水平上测量COX表达，而通过酶联免疫吸附测定法测量前列腺素（PG）E来评估COX活性。在标准的商业性COX-1/COX-2活性无细胞测定实验中完成了该研究。结果表明，CBD可显著抑制活化的PMN中COX-1和COX-2 mRNA的表达，然而，对PGE的产生没有任何显著影响。不过，在无细胞模型中，CBD能够对COX-2产生轻微但显著的直接抑制作用。CBD的作用发生在μM浓度范围内，这在人类使用该药物的治疗剂量时能够达到，表明这些发现具有临床相关性。
